On Tuesday, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was 5.24% up from the session before settling in for the closing price of $123.51. A 52-week range for JAZZ has been $99.06 – $134.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 15.82%. When this article was written, the company’s average yearly earnings per share was at 10.42%. With a float of $57.79 million, this company’s outstanding shares have now reached $60.44 million.
Considering the fact that the conglomerate employs 2800 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 77.79%, operating margin of 18.49%, and the pretax margin is 9.98%.
Jazz Pharmaceuticals plc (JAZZ) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Jazz Pharmaceuticals plc stocks. The insider ownership of Jazz Pharmaceuticals plc is 4.41%, while institutional ownership is 97.13%. The most recent insider transaction that took place on Feb 03 ’25, was worth 183,465. In this transaction Chairman & CEO of this company sold 1,500 shares at a rate of $122.31, taking the stock ownership to the 439,744 shares. Before that another transaction happened on Feb 03 ’25, when Company’s Officer proposed sale 1,500 for $122.31, making the entire transaction worth $183,465.
Jazz Pharmaceuticals plc (JAZZ) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 4.58 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.36% during the next five years compared to -3.53% drop over the previous five years of trading.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Trading Performance Indicators
You can see what Jazz Pharmaceuticals plc (JAZZ) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.97. Likewise, its price to free cash flow for the trailing twelve months is 6.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 6.94, a number that is poised to hit 5.79 in the next quarter and is forecasted to reach 22.10 in one year’s time.
Technical Analysis of Jazz Pharmaceuticals plc (JAZZ)
Compared to the last year’s volume of 0.55 million, its volume of 0.75 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 52.35%. Additionally, its Average True Range was 3.15.
During the past 100 days, Jazz Pharmaceuticals plc’s (JAZZ) raw stochastic average was set at 93.99%, which indicates a significant increase from 87.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.21% in the past 14 days, which was lower than the 27.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $122.71, while its 200-day Moving Average is $113.84. Nevertheless, the first resistance level for the watch stands at $133.32 in the near term. At $136.65, the stock is likely to face the second major resistance level. The third major resistance level sits at $141.81. If the price goes on to break the first support level at $124.83, it is likely to go to the next support level at $119.67. Now, if the price goes above the second support level, the third support stands at $116.34.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Key Stats
There are 60,455K outstanding shares of the company, which has a market capitalization of 7.86 billion. As of now, sales total 3,834 M while income totals 414,830 K. Its latest quarter income was 1,055 M while its last quarter net income were 215,060 K.
